Eledon Pharmaceuticals
Eledon Pharmaceuticals develops immune-modulating therapies for life-threatening conditions, with a focus on their lead investigational product, tegoprubart. The company is headquartered in Irvine, California, and conducts clinical trials in kidney transplantation, xenotransplantation, and ALS.
About Eledon Pharmaceuticals
Eledon Pharmaceuticals focuses on developing immune-modulating therapies to treat life-threatening conditions. The company is headquartered in Irvine, California. Their leading investigational product is tegoprubart, an anti-CD40L antibody that shows high affinity for the CD40 Ligand. Eledon is dedicated to creating treatments that improve both the longevity of organs and the quality of life for transplant recipients, encapsulated in their mission, 'One Transplant for Life.'
Research and Development
Eledon Pharmaceuticals conducts extensive preclinical and clinical studies to evaluate their therapies. They are currently conducting a randomized Phase 2 trial comparing tegoprubart versus standard of care for the prevention of rejection in kidney transplant recipients. In addition, they are conducting a single-arm Phase 1b clinical trial focused on using tegoprubart to prevent rejection in kidney transplant patients. The company also evaluates tegoprubart’s potential for use in other transplant types, including liver transplantation and xenotransplantation.
Tegoprubart: A Lead Investigational Product
Tegoprubart, an anti-CD40L antibody developed by Eledon Pharmaceuticals, is engineered to have a high affinity for the CD40 Ligand. This investigational product is a central focus for the company in its efforts to prevent organ rejection. Tegoprubart is currently being tested in various trials, including a Phase 1b single-arm clinical trial and a Phase 2 randomized trial, both aimed at determining its effectiveness in preventing kidney transplant rejection.
Clinical Trials and Studies
Eledon Pharmaceuticals is actively involved in several clinical trials to assess the efficacy of their therapies. A notable trial is the Phase 2 randomized study, which compares tegoprubart to the standard care methods for preventing kidney transplant rejection. The company's ongoing Phase 1b trial focuses on utilizing tegoprubart in a single-arm study for similar purposes. Additionally, Eledon is exploring the application of tegoprubart in other types of organ transplantations, including liver transplants and xenotransplantation.
Company Mission and Vision
The mission of Eledon Pharmaceuticals is encapsulated in the phrase 'One Transplant for Life.' The company aims to extend the longevity of transplanted organs while enhancing the overall health and quality of life for transplant recipients. By focusing on immune-modulating therapies, particularly through their investigational product tegoprubart, Eledon strives to bring transformative treatments to the field of transplantation.